Brief Summary
Metabolic diseases such as obesity and diabetes are modern day epidemics. Early life exposure to an adverse developmental environment, including environmental toxins, are linked to increased susceptibility to obesity, metabolic syndrome and type 2 diabetes. Although the mechanisms underlying the fetal origins of metabolic disease are poorly understood, strong evidence suggests that alterations in the epigenome play a critical role in this process. The central hypothesis of this proposal is that intrauterine exposure to benzo\[a\]pyrene leads to epigenetic changes which will have functional consequences and may be a marker for, or may contribute to, increased susceptibility to adverse outcomes in childhood including increased adiposity and the subsequent development of obesity, metabolic syndrome or diabetes. The goals of this proposal are to: 1) determine benzo\[a\]pyrene levels in umbilical cord blood of newborns, 2) determine whether benzo\[a\]pyrene exposure during pregnancy correlates with early onset of obesity and metabolic disease by examining the children at 12 and 24 months of age, 3) determine whether in utero benzo\[a\]pyrene exposure programs metabolic disease through alterations in DNA methylation and gene expression, and 4) determine the plasticity of the DNA methylation patterns in the same offspring at 12 months of age. The long-term goal of this project is to define biomarkers that identify neonates at "high-risk" for diminished attainment of full health potential, who can then be targeted for preventative measures.
Brief Title
Epigenetic and Developmental Effects of In Utero Exposure to Environmental Toxicants
Completion Date
Completion Date Type
Actual
Conditions
Full Term Infants
Environmental Exposures
Adiposity
Eligibility Criteria
Inclusion Criteria:
* Infants whose mothers were followed by the Obstetric Department at MMC, and
* Deliver a single healthy live term infant
Exclusion Criteria:
* Multiple gestation,
* Maternal depression,
* History of maternal smoking in the 3rd trimester of pregnancy,
* Infants in extremis,
* Apgar score \<7 at 5 min and umbilical artery pH ≤7.25,
* Chromosomal/congenital abnormalities,
* Congenital infections, and
* Inborn errors of metabolism
* Infants whose mothers were followed by the Obstetric Department at MMC, and
* Deliver a single healthy live term infant
Exclusion Criteria:
* Multiple gestation,
* Maternal depression,
* History of maternal smoking in the 3rd trimester of pregnancy,
* Infants in extremis,
* Apgar score \<7 at 5 min and umbilical artery pH ≤7.25,
* Chromosomal/congenital abnormalities,
* Congenital infections, and
* Inborn errors of metabolism
Inclusion Criteria
Inclusion Criteria:
* Infants whose mothers were followed by the Obstetric Department at MMC, and
* Deliver a single healthy live term infant
* Infants whose mothers were followed by the Obstetric Department at MMC, and
* Deliver a single healthy live term infant
Gender
All
Gender Based
false
Keywords
Term gestation
Environmental exposure
Benzo(a)pyrene
Polycyclic aromatic hydrocarbons
Adiposity
Cytosine methylation
Healthy Volunteers
No
Last Update Post Date
Last Update Post Date Type
Actual
Last Update Submit Date
Maximum Age
72 Hours
Minimum Age
1 Hour
NCT Id
NCT01815385
Org Class
Other
Org Full Name
Montefiore Medical Center
Org Study Id
12-12-428
Overall Status
Completed
Primary Completion Date
Primary Completion Date Type
Actual
Official Title
Early Life Exposure to Polycyclic Aromatic Hydrocarbons: Metabolic Perturbations and Epigenetic Biomarkers
Primary Outcomes
Outcome Description
Assessments will be performed within 72 hours of birth and at 1 and 2 years of age.
Outcome Measure
Measure indices of adiposity in enrolled patients
Outcome Time Frame
up to 24 months
Outcome Description
Benzo(a)pyrene levels will be measured in cord blood samples obtained at birth and in peripheral blood samples obtained at 12 months of age.
Outcome Measure
Measure benzo(a)pyrene levels in blood samples
Outcome Time Frame
up to 12 months of age
Outcome Description
Levels of tobacco by-products will be measured in cord blood samples obtained at birth and in peripheral blood samples obtained at 12 months of age.
Outcome Measure
Measure tobacco by-products in blood samples
Outcome Time Frame
up to 12 months of age
Outcome Description
Cytosine methylation changes in CD3+ T-lymphocytes will be characterized in cord blood and in a peripheral blood sample obtained at 12 months of age.
Outcome Measure
Characterize cytosine methylation changes in CD3+ T-lymphocytes
Outcome Time Frame
up to 12 months of age
Secondary Ids
Secondary Id
1-13-CE-06
Start Date
Start Date Type
Actual
Status Verified Date
First Post Date
First Post Date Type
Estimated
First Submit Date
First Submit QC Date
Study Population
Mother-baby pairs will be recruited.
Std Ages
Child
Maximum Age Number (converted to Years and rounded down)
0
Minimum Age Number (converted to Years and rounded down)
0
Investigators
Investigator Type
Principal Investigator
Investigator Name
Mamta Fuloria
Investigator Email
MFULORIA@montefiore.org
Investigator Phone
718-904-2821